| Literature DB >> 20724652 |
Eleni N Evagelidou1, Vasileios I Giapros, Anna S Challa, Vasileios K Cholevas, Georgios A Vartholomatos, Ekaterini C Siomou, Nikolaos I Kolaitis, Eleni T Bairaktari, Styliani K Andronikou.
Abstract
OBJECTIVE: To evaluate metabolic syndrome and cardiovascular disease risk factors in prepubertal children born large for gestational age (LGA) to nondiabetic, nonobese mothers. RESEARCH DESIGN AND METHODS: At 6-7 years of age, the comparison of various factors was made between 31 LGA and 34 appropriate-for-gestational-age (AGA) children: fibrinogen, antithrombin III, protein C and S, fasting insulin, glucose, homeostasis assessment model of insulin resistance (HOMA-IR) index, adiponectin, leptin, visfatin, IGF-1, IGF-binding protein (IGFBP)-1, IGFBP-3, lipids, and the genetic factors V Leiden G1691A mutation, prothrombin 20210A/G polymorphism, and mutation in the enzyme 5,10-methylenetetrahydrofolate-reductase gene (MTHFR-C677T).Entities:
Mesh:
Year: 2010 PMID: 20724652 PMCID: PMC2963515 DOI: 10.2337/dc10-1190
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 17.152
Characteristics, anthropometric indices, and indices of the prothrombotic state and insulin resistance, components of the IGFs-axis, lipid profile, and adipocytokines (means ± SD) at prepuberty of children born LGA (birth weight ≥95th percentile) or AGA (birth weight 10th–90th percentile)
| Characteristics and parameters | LGA group | AGA group | |
|---|---|---|---|
|
| 31 | 33 | — |
| Age (years) | 6.5 ± 0.5 | 6.4 ± 0.6 | ns |
| Body weight (kg) | 32 ± 8 | 24 ± 6 | <0.01 |
| Body height (cm) | 126 ± 8 | 119 ± 9 | 0.08 |
| Waist circumference | 0.80 ± 0.98 | 0.06 ± 1.3 | 0.05 |
| BMI | 0.80 ± 0.80 | −0.20 ± 0.8 | <0.001 |
| Systolic BP | 0.49 ± 0.41 | 0.41 ± 0.43 | ns |
| Diastolic BP | 0.71 ± 0.35 | 0.51 ± 0.5 | ns |
| Prothrombin time (s) | 13.29 ± 0.53 | 13.2 ± 0.52 | ns |
| APTT (s) | 37.04 ± 22 | 38.64 ± 24 | ns |
| Fibrinogen (μmol/l) | 7.67 ± 0.9 | 10.05 ± 2.3 | ≤0.0001 |
| Antithrombin III (%) | 104 ± 50 | 107 ± 69 | ns |
| Protein C (%) | 99 ± 11 | 97 ± 18 | ns |
| Protein S (%) | 69 ± 24 | 70 ± 19 | ns |
| Fasting glucose (mmol/l) | 5.1 ± 0.5 | 4.9 ± 0.6 | ns |
| Fasting insulin (pmol/l) | 48.6 ± 20.1 | 27 ± 24.3 | <0.01 |
| FGIR | 0.11 ± 0.05 | 0.25 ± 0.11 | ≤0.0001 |
| HOMA-IR | 1.5 ± 0.6 | 0.8 ± 0.7 | <0.01 |
| IGF-1 (μg/l) | 189 ± 115 | 140 ± 84 | 0.06 |
| IGFBP-1 (μg/l) | 84 ± 33 | 88 ± 31 | ns |
| IGFBP-3 (mg/l) | 2.6 ± 1.1 | 3.9 ± 0.8 | ≤0.0001 |
| 4.53 ± 0.6 | 4.45 ± 0.6 | ns | |
| HDL (mmol/l) | 1.41 ± 0.2 | 1.45 ± 0.2 | ns |
| Triglycerides (mmol/l) | 0.65 ± 0.1 | 0.71 ± 0.2 | ns |
| Lipoprotein(a) (μmol/l) | 0.09 ± 0.1 | 0.3 ± 0.2 | <0.001 |
| Adiponectin (mg/l) | 16.3 ± 6 | 14.7 ± 5 | ns |
| Leptin (μg/l) | 52 ± 23 | 31 ± 19 | ≤0.01 |
| Visfatin (μg/l) | 13.3 ± 6 | 13 ± 5 | ns |
APTT, activated partial thromboplastin time; FGIR, fasting glucose-to-insulin ratio; ns, not significant (P > 0.05).